Induced Pluripotent Stem Cells in Regenerative Medicine and Disease Modeling

Author(s): Graham G. Walmsley, Jeong Hyun, Adrian McArdle, Kshemendra Senarath-Yapa, Michael S. Hu, Michael T. Chung, Victor W. Wong, Michael T. Longaker, Derrick C. Wan

Journal Name: Current Stem Cell Research & Therapy

Volume 9 , Issue 2 , 2014

Become EABM
Become Reviewer

Abstract:

In 2006, Dr. Yamanaka created the induced pluripotent stem cell (iPSC) by reprogramming adult fibroblasts back to an immature, pluripotent state. Effectively bypassing the ethical constraints of human embryonic stem cells, iPSCs have expanded the horizons of regenerative medicine by offering a means to derive autologous patient-matched cells and tissues for clinical transplantation. However, persisting safety concerns must be addressed prior to their widespread clinical application. In this review, we discuss the history of iPSCs, derivation strategies, and current research involving gene therapy and disease modeling. We review the potential of iPSCs for improving a range of cell-based therapies and obstacles to their clinical implementation.

Keywords: Cell therapy, disease modeling, induced pluripotent stem cells, reprogramming, tissue regeneration, tissue engineering.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 2
Year: 2014
Page: [73 - 81]
Pages: 9
DOI: 10.2174/1574888X09666131217004137
Price: $65

Article Metrics

PDF: 66